Armenia
Tuberculosis profile
| High MDR-TB burden |
Population  2012 3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.19 (0.15–0.23) 6.3 (5.1–7.6)
Mortality (HIV+TB only) <0.01 (<0.01–0.012) 0.31 (0.26–0.4)
Prevalence  (includes HIV+TB) 2.4 (1.1–4.1) 79 (37–137)
Incidence  (includes HIV+TB) 1.5 (1.3–1.8) 52 (43–61)
Incidence (HIV+TB only) 0.038 (0.032–0.045) 1.3 (1.1–1.5)
Case detection, all forms (%) 79 (67–95)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 315 (28) Relapse 90 (23)
Smear-negative 553 (49) Treatment after failure 6 (2)
Smear-unknown / not done 0 (0) Treatment after default 9 (2)
Extrapulmonary 255 (23) Other 290 (73)
Other 0 (0)      
Total new 1 123   Total retreatment 395  
           
Other (history unknown) 0        
Total new and relapse 1 213   Total cases notified 1 518  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 4.6 3.5 1.6
Age < 15 1 10 26
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 1.7
Drug susceptibility testing (per 5 million population) 1.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 63   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 84  
Retreatment 68  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 518 (100)
HIV-positive TB patients 79 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 55 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 55 (70)
HIV-positive people screened for TB 223  
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 9.4 (7–12) 43 (38–49)
MDR-TB cases among notified pulmonary
TB cases
82 (61–110) 170 (150–190)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 420 (94%) 91 (23%) 511
Laboratory-confirmed MDR-TB cases 57 35 92
Patients started on MDR-TB treatment     101
Financing TB control 2013
National TB programme budget (US$ millions) 5.4
% Funded domestically 73%
% Funded internationally 27%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data